Novocure’s device for treating brain metastases rejected by FDA
Novocure's Optune Mya uses the company's TTFields therapy, designed to exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.
The post Novocure’s device for treating brain metastases rejected by FDA appeared first on Medical Device Network .